论文信息 - Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. - 字舞流文

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.

A. Nademanee | P. Stiff | V. Bachanova | T. Masszi | J. Walewski | J. Sweetenham | C. Moskowitz | S. Viviani | M. Abidi | A. Sureda | J. Hołowiecki | C. Lee | E. Agura | A. Chen | Teresa McClendon | J. Lisano